NCT04978818View on ClinicalTrials.gov

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
Haemophilus Influenzae Type B Infection
Interventions
DRUG

Vaxelis

Eligible infants will be block randomized to one of two study arms.

DRUG

PedvaxHIB

Eligible infants will be block randomized to one of two study arms.

Trial Locations (5)

86503

Chinle Center for Indigenous Health, Chinle

86504

Fort Defiance Center for Indigenous Health, Fort Defiance

87301

Gallup Center for Indigenous Health, Gallup

87420

Shiprock Center for Indigenous Health, Shiprock

99508

Alaska Native Medical Center, Anchorage

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Johns Hopkins Bloomberg School of Public Health

OTHER